FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi

Third biosimilar approved in US brings another iteration of FDA thinking on labeling and naming; etanercept-szzs, which references Amgen's Enbrel, suggests agency might be backtracking on its suffix policy.

SandozNorvatisDiv_1200

"Szzs" is probably a combination of letters only a linguist could love. But for sponsors hoping that FDA might change its policy on suffixes for biosimilars, it’s a syllable in the right direction. The Aug. 30 approval of Sandoz Inc.'s Erelzi (etanercept-szzs) means that the agency has now used three different approaches for adding suffixes for each of the three biosimilars it has approved – going from meaningful to random and now back toward somewhat meaningful.

Erelzi, which references Amgen Inc.'s TNF inhibitor Enbrel (etanercept), is Sandoz's second biosimilar approved in the US. The company's...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics